Evaluate Pharma：2024年细胞与基因疗法市场格局研究报告：机遇及挑战（英文版）

The landscape for cell and gene therapies has been evolving over the past few years with a rise in available treatments for rare and life-threatening diseases in the last year alone. This is despite generally high costs of R&D and manufacturing, coupled with the infancy of scientific understanding compared to other areas of science. Despite the increasing volume of gene therapy assets targeting hematological malignancies, significant market potential exists, driven by the complexities in